Halcon Resources (HK) - FREE Research Report

Obut Tina S who is VP, Corporate Reserves at Halcon Resources bought 5,000 shares at $4.67 on Nov. 6, 2013. Following this transaction, the VP, Corporate Reserves owned 179,010 shares meaning that the stake was reduced by 2.87% with the 5,000 share transaction.

Cusack Charles E III who is EVP, Chief Operating Officer at Halcon Resources bought 20,000 shares at $4.75 on Nov. 6, 2013. Following this transaction, the EVP, Chief Operating Officer owned 432,240 shares meaning that the stake was reduced by 4.85% with the 20,000 share transaction.

The shares most recently traded at $4.53, down $0.22, or 4.86% since the insider transaction. Historical insider transactions for Halcon Resources go as follows:

  • 12-Week # shares bought: 70,000
  • 24-Week # shares bought: 5.9 million

The average volume for Halcon Resources has been 6.0 million shares per day over the past 30 days. Halcon Resources has a market cap of $2.1 billion and is part of the basic materials sector and energy industry. Shares are down 26.16% year to date as of the close of trading on Wednesday.

Halcon Resources Corporation, an independent energy company, engages in the acquisition, production, exploration, and development of onshore oil and natural gas properties in the United States. Currently there are 7 analysts that rate Halcon Resources a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HK - FREE

TheStreet Quant Ratings rates Halcon Resources as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Halcon Resources Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round